Zimmer Biomet Holdings, Inc. ZBH
Composite 47/100; the shares have moved about 32% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 35/100 — a moderate mark against it.
Valuation ranks 70/100 — a moderate point in its favour. Income ranks 58/100 — a slight point in its favour.
Growth ranks 35/100 — a moderate mark against it. Quality ranks 37/100 — a moderate mark against it. Balance-sheet strength ranks 42/100 — a slight mark against it.
What the company does Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive products, sports medicine devices, trauma products, and craniomaxillofacial solutions. Its portfolio includes knee and hip implants, soft-tissue repair systems, and digital/robotic surgical technologies leveraging AI and data analytics.
Key financials Gross margin is 69.9% with operating and net margins at 18.0% and 9.5%, respectively. Revenue grew 7.2% while EPS declined -20.1%. ROE is 6.4% and ROA is 4.0%; debt/equity is 0.60 and net debt/EBITDA is 2.79. Forward P/E is 11.51 and EV/EBITDA is 11.03.
Stock health Sideravia scores the stock average overall (50.6/100), with strength in valuation (57.0) but weaker growth (45.9) and income (43.7). Piotroski F-Score is 5/9 and current ratio is 1.69. Twelve-month performance is -3.47% with RSI(14) at 61.60.
Price vs fair value The stock trades at a discount of 6.50% versus the analyst mean target of 107.57. - Zacks questions retention appeal amid margin pressures (Zacks) - Simply Wall St notes the stock remains discounted after a 28% five-year slide (Simply Wall St) - Trefis highlights margin expansion in adjacent medtech as a competitive signal (Trefis)
Looking forward Forward P/E of 11.51 and PEG of 0.11 suggest valuation support relative to growth. Digital and robotic surgery adoption may drive long-term margin expansion, offsetting near-term EPS headwinds. Analysts cite valuation as a key consideration while monitoring adoption of integrated technologies.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.